125 related articles for article (PubMed ID: 28700051)
1. Pharmacotherapeutic follow-up of patients with Chagas disease using benznidazole: drug-related problems and pharmaceutical interventions.
Correia JPR; Costa ACD; Rocha EA; Quidute ARP; Cândido DDS; Ponciano ÂMS; Fonteles MMF; Oliveira MF
Rev Soc Bras Med Trop; 2017; 50(3):334-340. PubMed ID: 28700051
[TBL] [Abstract][Full Text] [Related]
2. Technological innovation strategies for the specific treatment of Chagas disease based on Benznidazole.
Ferraz LRM; Alves AÉG; Nascimento DDSDS; Amariz IAE; Ferreira AS; Costa SPM; Rolim LA; Lima ÁAN; Rolim Neto PJ
Acta Trop; 2018 Sep; 185():127-132. PubMed ID: 29452113
[TBL] [Abstract][Full Text] [Related]
3. Characterization of adverse reactions to benznidazole in patients with Chagas disease in the Federal District, Brazil.
Gontijo MKCL; Arruda HMBDS; Noronha EF; Toledo MI
Rev Soc Bras Med Trop; 2020; 53():e20190150. PubMed ID: 31994658
[TBL] [Abstract][Full Text] [Related]
4. Tolerance of benznidazole in a United States Chagas Disease clinic.
Miller DA; Hernandez S; Rodriguez De Armas L; Eells SJ; Traina MM; Miller LG; Meymandi SK
Clin Infect Dis; 2015 Apr; 60(8):1237-40. PubMed ID: 25601454
[TBL] [Abstract][Full Text] [Related]
5. [Adverse reactions in Chagas disease patients treated with benznidazole, in the State of Ceará].
de Pontes VM; Souza Júnior AS; Cruz FM; Coelho HL; Dias AT; Coêlho IC; Oliveira Mde F
Rev Soc Bras Med Trop; 2010; 43(2):182-7. PubMed ID: 20464150
[TBL] [Abstract][Full Text] [Related]
6. Side effects of benznidazole treatment in a cohort of patients with Chagas disease in non-endemic country.
Carrilero B; Murcia L; Martínez-Lage L; Segovia M
Rev Esp Quimioter; 2011 Sep; 24(3):123-6. PubMed ID: 21947093
[TBL] [Abstract][Full Text] [Related]
7. Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières.
Yun O; Lima MA; Ellman T; Chambi W; Castillo S; Flevaud L; Roddy P; Parreño F; Albajar Viñas P; Palma PP
PLoS Negl Trop Dis; 2009 Jul; 3(7):e488. PubMed ID: 19582142
[TBL] [Abstract][Full Text] [Related]
8. Adverse systemic reaction to benznidazole.
Coronel MV; Frutos LO; Muñoz EC; Valle DK; Rojas DH
Rev Soc Bras Med Trop; 2017; 50(1):145-147. PubMed ID: 28327820
[TBL] [Abstract][Full Text] [Related]
9. Should benznidazole be used in chronic Chagas' disease?
Bestetti RB
Lancet; 1997 Mar; 349(9052):653. PubMed ID: 9057760
[No Abstract] [Full Text] [Related]
10. Arthritis and benznidazole: more closely related than we thought.
Aldasoro E; Pinazo MJ; Oliveira I; Munoz J; Posada E; Requena-Méndez A; Serret N; Gascon J
Antimicrob Agents Chemother; 2015 Jan; 59(1):727-9. PubMed ID: 25385100
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the toxicity of two treatment schemes with benznidazole for chronic Chagas disease: a prospective cohort study in two Spanish referral centres.
Crespillo-Andújar C; López-Vélez R; Trigo E; Norman F; Díaz-Menéndez M; Monge-Maillo B; Arsuaga M; Pérez-Molina JA
Clin Microbiol Infect; 2020 Mar; 26(3):384.e1-384.e4. PubMed ID: 31740423
[TBL] [Abstract][Full Text] [Related]
12. Side effects of benznidazole as treatment in chronic Chagas disease: fears and realities.
Viotti R; Vigliano C; Lococo B; Alvarez MG; Petti M; Bertocchi G; Armenti A
Expert Rev Anti Infect Ther; 2009 Mar; 7(2):157-63. PubMed ID: 19254164
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety assessment of different dosage of benznidazol for the treatment of Chagas disease in chronic phase in adults (MULTIBENZ study): study protocol for a multicenter randomized Phase II non-inferiority clinical trial.
Molina-Morant D; Fernández ML; Bosch-Nicolau P; Sulleiro E; Bangher M; Salvador F; Sanchez-Montalva A; Ribeiro ALP; de Paula AMB; Eloi S; Correa-Oliveira R; Villar JC; Sosa-Estani S; Molina I
Trials; 2020 Apr; 21(1):328. PubMed ID: 32293523
[TBL] [Abstract][Full Text] [Related]
14. A clinical adverse drug reaction prediction model for patients with chagas disease treated with benznidazole.
Sperandio da Silva GM; Mediano MF; Alvarenga Americano do Brasil PE; da Costa Chambela M; da Silva JA; de Sousa AS; Xavier SS; Rodrigues da Costa A; Magalhães Saraiva R; Hasslocher-Moreno AM
Antimicrob Agents Chemother; 2014 Nov; 58(11):6371-7. PubMed ID: 25114135
[TBL] [Abstract][Full Text] [Related]
15. High frequency of adverse reactions and discontinuation with benznidazole treatment for chronic Chagas disease in Milan, Italy.
Antinori S; Grande R; Bianco R; Traversi L; Cogliati C; Torzillo D; Repetto E; Corbellino M; Milazzo L; Galli M; Galimberti L
Clin Infect Dis; 2015 Jun; 60(12):1873-5. PubMed ID: 25805302
[No Abstract] [Full Text] [Related]
16. Low Incidence of Adverse Effects Using a Progressive Regimen of Benznidazole in Chagas Disease.
Navarrete MN; Gutiérrez-Gutiérrez B; de Arellano-Ramos R; Del Castillo SF; Domínguez-Castellano Á
Clin Infect Dis; 2016 Apr; 62(8):1052. PubMed ID: 26769725
[No Abstract] [Full Text] [Related]
17. Long term evaluation of etiological treatment of chagas disease with benznidazole.
Cancado JR
Rev Inst Med Trop Sao Paulo; 2002; 44(1):29-37. PubMed ID: 11896410
[TBL] [Abstract][Full Text] [Related]
18. A study of photostability and compatibility of the anti-chagas drug Benznidazole with pharmaceutics excipients.
Santos FL; Rolim LA; Figueirêdo CB; Lyra MA; Peixoto MS; Ferraz LR; Soares-Sobrinho JL; Neves de Lima ÁA; Lima Leite AC; Rolim Neto PJ
Drug Dev Ind Pharm; 2015 Jan; 41(1):63-9. PubMed ID: 24134564
[TBL] [Abstract][Full Text] [Related]
19. New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients.
Álvarez MG; Hernández Y; Bertocchi G; Fernández M; Lococo B; Ramírez JC; Cura C; Albizu CL; Schijman A; Abril M; Sosa-Estani S; Viotti R
Antimicrob Agents Chemother; 2016 Feb; 60(2):833-7. PubMed ID: 26596935
[TBL] [Abstract][Full Text] [Related]
20. Nifurtimox therapy for Chagas disease does not cause hypersensitivity reactions in patients with such previous adverse reactions during benznidazole treatment.
Pérez-Molina JA; Sojo-Dorado J; Norman F; Monge-Maillo B; Díaz-Menéndez M; Albajar-Viñas P; López-Vélez R
Acta Trop; 2013 Aug; 127(2):101-4. PubMed ID: 23583863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
